Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment
The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...
Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025
Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...
Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...
China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management
The National Medical Products Administration (NMPA) of China has issued a new set of regulations...
JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies
Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...
Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...
Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance
Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...
Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...
Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia
Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...
CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology
CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...
Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor
Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...
Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China
Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...
Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...
Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079
Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...
Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare
Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...
Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...
Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital
Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...
Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction
Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...